🔗 Share this article

While the US undertakes historic revisions to its vaccine recommendations, one figure has surfaced somewhat surprisingly: Tracy Beth Høeg, a Danish American sports medicine doctor and public health researcher who first made her name by expressing skepticism about Covid shots in the pandemic and has zeroed in on possible fatalities following Covid immunization in her short position at the FDA.

Scheduled Shifts to Pediatric Immunization Schedule

Health officials were set to unveil radical changes to the childhood immunization program earlier this month, aligning the US with the Danish national calendar, according to reports – a significant shift that would put the US at odds with a large portion of the world with little proof for benefit. The announcement has been delayed until the coming year.

Rather than the director of the vaccine center, Dr. Høeg is scheduled to address the audience at the meeting. She was recently named acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to lead the center this calendar year.

A Shift at the FDA

The acting appointment could signify a tighter collaboration between the drug and vaccine centers as Dr. Høeg and Dr. Prasad consolidate power at the FDA – and it suggests a renewed priority upon rolling back previously authorized immunizations at the FDA.

Dr. Høeg has repeatedly called for halting specific pediatric immunization guidelines in the US so as to align more similar to Denmark's approach, a country with comprehensive healthcare and a citizenry roughly the size of the state of Wisconsin.

To date comments, she has persisted in emphasizing on immunizations – typically the responsibility of Dr. Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of medication approval.

Doubts Over Background

Dr. Høeg has no obvious experience in pharmaceutical research, regulation or administrative roles, which has been standard for previous heads of the CBER. She has worked at the FDA as a senior adviser to the commissioner and CBER since earlier this year.

“She doesn’t seem to have the requisite experience” for overseeing the drug-regulation department, remarked Dr. Jonathan Howard. “She lacks experience running a randomized controlled trial. She lacks experience in running a sizeable institution. She lacks background in drug approvals.”

Previous heads of the center would “understand legal statutes and the science of medication creation”, said a former acting FDA commissioner. “Objectively, she doesn’t have the kind of background that former directors who led CBER have had.”

CDER has an vast workload at the agency, the former commissioner emphasized.

“The public just pays attention on the novel medication approvals, but the generic drug division authorizes numerous generic medications. There is also a biologic copycat branch, non-prescription drug unit and so forth, and every single one must be supervised,” Woodcock noted. “The responsibility you overlook, that’s the thing that I always told people is going to cause problems.”

There is also, a major administrative aspect to the position, which supervises over 5,000 employees. “It’s a huge administrative position, if you execute it properly,” she said.

Response and Contentious Programs

In response to questions about Høeg’s qualifications and whether this appointment represents greater collaboration among regulatory chiefs on immunizations, a press secretary said that the “concerns rely on flawed assumptions”.

“Her resume aligns with the responsibilities of her job,” the representative stated, noting the months Dr. Høeg spent guiding the agency head on “medication safety and regulatory science, including computerized risk analysis and shot safety tracking”.

In her interim role, Høeg takes over the agency head's controversial expedited review system, a contentious expedited therapy clearance system that reportedly concerned her preceding directors. “By what process are these therapies being picked for this fast-track system? Who is making the decisions?” Howard questioned. “There is a lot of secrecy occurring at the regulatory body right now.”

In general, he remarked, “the FDA looks to be trending towards laxer regulations of all drugs, except for shots.”

Documented Past Work on Vaccines

With immunizations, Dr. Høeg has a more established, if problematic, history, Howard said. She released a analysis using non-validated crowd-sourced reports to estimate the frequency of myocarditis after Covid immunization. She consulted for the Florida top health official Joseph Ladapo, who was said to have changed statistics to imply Covid vaccines are riskier than they are.

Included in her “wish list” for the incoming government featured changing rules for novel immunizations and halting “optional” immunizations, she said following the vote on a audio program. At the agency, Dr. Høeg has allegedly proposed barring teenage boys from getting COVID-19 vaccines.

“She’s an complete ideologue who starts off with her preconceived notions and reverse-engineers to retrofit the evidence in a very disingenuous, untruthful way,” Dr. Howard said.

Gaining Influence and a “Campaign of Retribution”

Høeg became part of other skeptics, {like|